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Background: In cystic ﬁbrosis (CF) patients the right ventricle (RV) suffers a progressive deterioration, but it is not clear when these changes
begin. The aim of this study was to analyze the RV function in CF patients with mild respiratory disease.
Methods: Color-Doppler-Echocardiographic studies were prospectively performed in CF adolescent patients and an age-matched control group.
Findings were correlated with pulmonary function tests (PFT), genotype, chronic bacterial colonization, pancreatic status and clinical scores. Only
patients with mild CF were selected.
Results: Thirty seven CF patients and 40 healthy controls were recruited. In CF patients all echocardiographic parameters were abnormal compared
to controls. Doppler analysis showed slightly elevated pulmonary artery pressure values, and abnormal relaxation and systolic function for all
indexes. No correlation was found with any of the features studied.
Conclusions: In CF patients, abnormalities in the structure and function of the RV may be present at early stages of the disease. These
abnormalities are subclinical and do not correlate with clinical scores, PFT, genotype, chronic bacterial colonization or pancreatic insufﬁciency.
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Cystic fibrosis (CF) represents the most common lethal genet-
ic disease in Caucasians. It occurs in approximately 1 of every
3400 live births among Caucasians [1]. Technical advances and
early referral to a specialist center with a better medical man-
agement have significantly extended life expectancy into
adulthood [2].
In CF, progressive worsening in lung structure and function
due to chronic infection and inflammation leads to an increas-
ing morbidity and mortality rates. The right ventricle (RV) suf-
fers a progressive deterioration parallel to the severity of the
disease [3], but it is not clear whether these changes occur
when clinical signals of pulmonary disease are mild or when
they become severe. As in other chronic pulmonary diseases,
cardiac involvement in CF has been associated with the pro-
gression of lung disease and the presence of hypoxia, but it isby Elsevier B.V. All rights reserved.
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related to cystic fibrosis transmembrane conductance regulator
(CFTR) dysfunction. Also, there are no studies evaluating cardiac
function in CF patients with mild lung function impairment. Fur-
thermore, cardiac findings have not yet been correlated with
the presence of chronic bacterial colonization, pancreatic
insufficiency, or with a specific genotype, at this range of age.
The aim of this study was to analyze the RV in a cohort of
adolescents with mild CF, using M-mode, 2D, and Doppler
echocardiography to evaluate the effects of the disease on RV
anatomy (thickness and dimension) and function (systolic
and diastolic). Also, to estimate the pulmonary artery systolic
pressure (PASP) through the analysis of Doppler curves of
tricuspid inflow and pulmonary forward flow. In addition, we
aimed to compare these findings with the pulmonary function
tests (PFT), genotype, pancreatic status, type of chronic
bacterial colonization, and clinical scores of severity. We hy-
pothesized that CF patients with mild lung disease have an al-
teration in cardiac function that is independent of the degree of
pulmonary impairment.2. Methods
2.1. Study subjects
A prospective study was conducted in our Institution that was
approved by the Ethical Committee (R-0015/10). Thirty seven
adolescent patients with cystic fibrosis (20 males and 17 females
age range 12 to 18 years), were recruited from the outpatient
clinic of the Cystic Fibrosis Unit, all of them clinically stable,
with no respiratory exacerbation in the previous six month.
All had genotype and sweat test confirmation, and only patients
with mildly reduced FEV1 were selected [4]. Written consent was
obtained from all the patients or their parents.
The control group consisted of 40 age-matched healthy adoles-
cents (18 males and 22 females age range 12.1 to 17.5 years).
They were recruited at the cardiology outpatient clinic where
they were investigated for non-organic murmur or functional
thoracic pain. Patients with previous history of cardiovascular
or systemic disease were excluded. All had entirely normal
physical findings and laboratory evaluations.2.2. Echocardiographic studies
A comprehensive protocol was designed in our department
to study the right ventricular anatomy and function, both sys-
tolic and diastolic. This included M-mode and 2D images,
Doppler flow velocities of pulmonary and tricuspid valves,
four-chamber view right ventricular area mapping, and tissue
Doppler analysis of tricuspid annulus.
All the echocardiographic studies were performed by the
same observer who was blinded to the clinical status of the
patients. Analysis of the data was performed off-line by two re-
searchers who were unaware of the physical conditions and
grouping of the patients. Five consecutive cardiac cycles were
obtained for each parameter and averaged.M-mode, two-dimensional and Doppler echocardiography
studies were performed by using an ultrasound system (model
HD11-XE, Philips Medical Systems, Bothell, WA) and a
S8-3 MHz transducer. Echocardiographic images were obtained
from the parasternal and apical windows, with the patient in left
lateral decubitus. Images were obtained at a rate of 50 mm/s
and continuous 1-channel electrocardiographic monitoring was
used throughout the study.
Echocardiographic M-mode measurements were obtained
according to recommendations of the American Society of Echo-
cardiography [5]. The RV anterior wall thickness (RVAW) and
end-diastolic dimension (RVEDD) were measured at end diastole
from the parasternal long-axis view, and corrected for body
surface area (BSA).
The tricuspid annular plane systolic excursion (TAPSE) was
measured on the M-mode tracing in the apical four-chamber
window and was defined as the difference in the displacement
of the RV base during diastole and systole. RV fractional area
change (RVFA) was calculated by using the following formula:
(end-diastolic area−end-systolic area)/end-diastolic area [6].
The right ventricular pre-ejection period (RPEP) was mea-
sured from the Q wave of the electrocardiogram to the onset
of pulmonary forward flow. The acceleration time (ACT) and
right ventricular ejection time (RVET) were measured from the
onset of flow to the peak velocity of flow and the end of flow,
respectively. The RPEP/RVET and ACT/RVET ratios were cal-
culated. In the absence of a significant tricuspid regurgitation,
these measurements allow to indirectly estimate the presence of
elevated PASP.
RV diastolic indexes were assessed from the apical four-
chamber view at end expiration. A 4-mm pulsed Doppler sample
volume was positioned at the level of the tricuspid valve, just at
the tips of the tricuspid leaflets during diastole. E-wave (early
filling), A-wave (late filling), and E/A ratio indexes were ob-
tained. Tricuspid regurgitation, when present, was used to esti-
mate PASP, by adding 10 mm Hg to the tricuspid regurgitation
gradient.
Tissue Doppler echocardiography (TDE) was performed in
apical four-chamber view with the pulsed-wave sample volume
(length=4 mm) placed at the lateral tricuspid annulus. Measure-
ments included the peak systolic annular velocity (ST-wave),
peak early diastolic (ET-wave) and late diastolic (AT-wave)
tricuspid annular velocity. The ET/AT ratio was calculated.
To test the homogeneity of the CF group, we also compared
patients with FEV1% greater and less than 85% predicted values.
2.3. Pulmonary function tests
All cystic fibrosis patients underwent spirometry on the
same day of the echocardiographic study. A Jaeger Masterscope
Spirometer with Version 4.3 Jaeger Software (Jaeger, Hoechberg,
Germany) was used to record inspiratory and expiratory flows.
The tracings were obtained with the patients in the sitting position
and the best of three tracings was used for analysis. Forced expi-
ratory volume in 1 s (FEV1) and forced vital capacity (FVC)
were expressed as percent predicted for the patient's age, height
and weight according to prediction equations standardized in
Table 1
Lung function tests, clinical characteristics and scores in patients with cystic
fibrosis (CF).
Variable Value Range
FEV1 2.6±0.7 1.41–4.07
FEV1% 93.2±14.7 70.32–123.61
FVC 3,2±0.8 1.70–4.75
FVC% 99.1±11.7 69.09–124.96
Shwachman (SK) score 88.4±6.4 74–98
Brasfield score 19.3±3.0 14–23
Genotype: ΔF508/ΔF508 10
(No. cases) ΔF508/other 16
Other/other 11
Pancreatic status: sufficient 10
(No. cases) insufficient 27
Chronic infection: absent 6
(No. cases) P. aeruginosa 5
S. aureus 26
Values are expressed as mean±SD (standard deviation).
FVC = forced vital capacity; FEV1 = forced expiratory volume in 1 s.
(%) = percent of predicted value.
Table 2
Characteristics of CF patients and controls.
Characteristics CF group Controls p value
Subjects n 37 40
Sex male/female 20/17 18/22
Age (yrs) 14.7±1.8 14.6±1.4 0.662
Height (cm) 157.4±10.2 163.3±8.2 0.006*
Body weight (kg) 49.1±11.5 54.0±8.8 0.040*
Body surface area (BSA) (m2) 1.47±0.21 1.57±0.16 0.015*
Body mass index (kg/m2) 19.6±2.9 20.1±1.9 0.319
Values are expressed as mean±SD; (*): significant.
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FEV1% values N70%, according to ATS/ERS guidelines [4].
2.4. Clinical studies
Genotype was defined based on the number ofΔF508 CFTR
mutations carried by each individual as homozygous ΔF508/
ΔF508, heterozygous ΔF508/other, or other/other. Pancreatic
status was described as insufficient if the subject had diagnosed
pancreatic insufficiency or was taking supplemental pancreatic
enzymes.
Chronic bacterial colonization was described as more than 3
positive sputum cultures for at least 6 months. Patients were
divided into three groups: those colonized by Pseudomonas
aeruginosa, Staphylococcus aureus, or non-colonized.
Clinical scores were calculated according to the methods of
Shwachman–Kulczycki (SK) [8], and Brasfield [9]. SK scores
were calculated from a composite of four categories: general
activity, physical examination, nutrition, and chest radiographic
in clinically stable patients, free of pulmonary exacerbations.
Chest radiographs were scored utilizing the Brasfield clinical
scoring system based on five categories according to the chest
roentgenogram: air trapping, linear markings, nodular-cystic le-
sions, large lesions, and overall severity.
2.5. Statistical analysis
SPSS 15.0 (SPSS Inc., Chicago, IL) was used for the statis-
tical analysis. Data are expressed as mean value±SD. Stu-
dent's t test was used to assess the significant differences of
mean values between patients and controls. Pearson's correla-
tion coefficient was used to assess statistically significant
correlations. A p valueb0.05 was considered statistically sig-
nificant. Normal distribution of the continuous values was
assessed by the Kolmogorov–Smirnov test. Regression lines
were adjusted to explore potential correlations between PFT
or clinical scores and echocardiographic findings.
3. Results
Clinical data of patients with CF are presented in Table 1.
Baseline characteristics of study patients and controls are pre-
sented in Table 2. The interobserver reproducibility was good.
Intraclass correlation coefficients (r value) between both
observers for all echocardiographic parameters were above 0.7.
M-mode findings (RVAW, RVEDD, and corrected by
BSA), and 2D findings (TAPSE and RVFA) in CF patients,
were significantly different from healthy controls (Table 3).
Doppler echocardiography findings (tricuspid E-wave, A-
wave, E/A ratio) were also different in CF patients compared
with the controls, with an increased A-wave and decreased
E-wave and E/A ratio for CF patients group. The acceleration
time of pulmonary artery flow was shorter in patients with CF
than in healthy subjects. RVET was also shorter in the CF
group compared to the control group, with a significant increase
in RPEP/RVET and a decrease in RVAT/RVET ratios (Table 3).
Tricuspid regurgitation was present in 12 CF patients (32%),and for this subgroup PASP was 26±8 mm Hg (range 14 to
39 mm Hg), with three patients over 30 mm Hg.
TDE revealed abnormal relaxation for all indexes in the CF
group compared to the controls, with an increase in AT-wave,
and decrease in ET-wave and ET/AT ratio. The ST-wave was
also shorter in the CF group (Table 3).
When patients with FEV1% values greater and less than
85% predicted were compared, RVET and RPEP/RVET ratio
showed significant differences, suggesting that mild elevation
of PASP could be present in the second group, although ACT
and ACT/RVET ratio values remained unchanged. No other
changes in the rest of anatomic or functional parameters were
found (Table 4).
Most of the CF subjects (73%) had pancreatic insufficiency.
Individuals homozygous for the ΔF508 CFTR mutation repre-
sented 27%, the heterozygous comprised 43.2%, and the rest
corresponded to 29.7%, of the entire study population. No cor-
relation was found in any of the echocardiographic parameters
with the status of the pancreas or specific genotype in the CF
group. RVEDD values for individuals with pancreatic insufficien-
cy were 22.8±4 mm, and for pancreatic sufficiency 21.2±4 (p
Table 3
Comparison of clinical and echocardiographic parameters between patients with
cystic fibrosis (CF) and controls.
Variable CF group Controls p value
Subjects n 37 40
RV geometry
RVAW (mm) 2.5±0.7 1.9±0.3 0.000*
RVAW/BSA 1.7±0.5 1.2±0.2 0.000*
RVEDD (mm) 22.3±4.0 19.7±3.5 0.003*
RVEDD/BSA 15.4±2.7 12.6±2.2 0.000*
RV systolic function
RVFA (%) 0.34±0.05 0.40±0.06 0.000*
TAPSE (mm) 20.9±3.4 23.0±2.8 0.007*
ST-wave (cm/s) 12.6±2.0 14.0±2.9 0.016*
RV diastolic function
E-wave (cm/s) 0.64±0.11 0.70±0.11 0.015*
A-wave (cm/s) 0.42±0.13 0.32±0.06 0.000*
E/A ratio 1.66±0.55 2.26±0.57 0.000*
ET-wave (cm/s) 14.7±3.2 17.9±2.9 0.000*
AT-wave (cm/s) 11.3±3.3 9.2±2.2 0.001*
ET/AT ratio 1.39±0.45 2.02±0.47 0.000*
PSAP estimation
RPEP (ms) 68.1±13.7 64.0±11.4 0.175
ACT (ms) 118.8±29.1 145.1±24.2 0.000*
RVET (ms) 309.4±30.1 330.3±26.4 0.002*
Ratio RPEP/RVET 0.22±0.05 0.19±0.04 0.012*
Ratio ACT/RVET 0.38±0.08 0.44±0.08 0.002*
Values are expressed as mean±SD; (*): significant.
ACT = right ventricular acceleration time; AT-wave = tissue Doppler late dia-
stolic tricuspid annular velocity; A-wave = tricuspid peak late diastolic filling
velocity; ET-wave = tissue Doppler peak early diastolic tricuspid annular veloc-
ity; E-wave = tricuspid peak early diastolic filling velocity; RPEP = right ven-
tricular pre-ejection period; RVAW = right ventricular anterior wall thickness;
RVEDD = right ventricular end-diastolic dimension; RVET: right ventricular
ejection time; RVFA = right ventricular fractional area change; ST-wave = tis-
sue Doppler peak systolic tricuspid annular velocity; TAPSE = tricuspid annular
plane systolic excursion.
Table 4
Comparison of clinical and echocardiographic parameters between CF patients
with FEV1% values greater and less than 85% predicted.
Variable N85% b85% p value
Subjects n 25 12
Age (yrs) 14.8±1.8 14.5±1.9 0.664
Body surface area (BSA) (m2) 1.49±0.21 1.41±0.19 0.255
RV geometry
RVAW (mm) 2.4±0.6 2.6±0.7 0.436
RVAW/BSA 1.7±0.5 1.9±0.4 0.238
RVEDD (mm) 22.6±4.2 21.7±3.6 0.567
RVEDD/BSA 15.4±3 15.5±2.1 0.925
RV systolic function
RVFA (%) 0.33±0.05 0.35±0.05 0.168
TAPSE (mm) 21.1±3.9 20.3±1.5 0.520
ST-wave (cm/s) 12.8±2.2 12.1±1.6 0.373
RV diastolic function
E-wave (cm/s) 0.64±0.12 0.62±0.08 0.604
A-wave (cm/s) 0.43±0.14 0.39±0.07 0.345
E/A ratio 1.65±0.60 1.68±0.44 0.907
ET-wave (cm/s) 14.4±3.0 15.4±3.6 0.418
AT-wave (cm/s) 11.6±3.7 10.8±2.0 0.523
ET/AT ratio 1.36±0.46 1.47±0.44 0.536
PSAP estimation
RPEP (ms) 65.6±11.9 73.1±16 0.125
ACT (ms) 118.4±31.6 119.8±24.3 0.888
RVET (ms) 316.6±31.1 294.6±22.4 0.036*
Ratio RPEP/RVET 0.21±0.05 0.25±0.06 0.029*
Ratio ACT/RVET 0.37±0.09 0.41±0.07 0.233
Values are expressed as mean±SD; (*): significant.
See Table 3 legend for expansion of abbreviations.
277A. Baño-Rodrigo et al. / Journal of Cystic Fibrosis 11 (2012) 274–2800.288); and RVFA% values were 0.34±0.05, and 0.34±0.06, re-
spectively. “Homozygous”, “heterozygous”, and “Other” genotype
groups showed values for RVEDD of 22.3±3.5; 21.6±4.7; and
23.5±3.5 mm; with no differences among them. The same results
were obtained for RVFA%, with values of 0.33±0.05; 0.34±0.05;
and 0.33±0.06; respectively.
Five patients (13.5%) were chronically colonized by P.
aeruginosa, 26 (70.3%) by methicillin sensitive S. aureus,
while the other 6 (16.2%) showed no colonization. When these
three groups were compared among them, no statistically dif-
ferences were found (values for RVEDD were 25.2±5.8 mm
for P. aeruginosa colonized patients; 21.4±3.5 mm for S. aureus
colonized patients; and 24.2±3.5 mm for non-colonized. Also
values for RVFA% were 0.35±0.07, 0.33±0.05, and 0.34±
0.05; respectively).
Linear regression analysis revealed no correlation between
any echocardiographic parameters and FEV1, FVC, SK or
Brasfield scores (Table 5).4. Discussion
In this study we have found abnormalities in RV anatomy,
systolic and diastolic function during adolescence, even be-
fore significant changes in PFT appeared. In addition, these
changes are not related to a specific genotype or type of chronic
colonization.
The RV disease in CF is thought to be secondary to raised
pulmonary artery pressure due to chronic hypoxia from the
progressive lung destruction [10]. As a result, cor pulmonale
defined as right ventricular enlargement and dysfunction, de-
velops, which may progress to right heart failure [11]. The in-
cidence and prognosis of clinical cor pulmonale failure in
infancy are not exactly known, but there are clinical [12], echo-
cardiographic [13], and autopsy studies [14] that have found a
high prevalence of RV hypertrophy and dilatation in patients
with CF. Finally, occurrence of RV failure secondary to cor
pulmonale is a poor prognostic sign.
Right ventricular dimension has been classically considered
to reflect the severity of cor pulmonale in CF [13,15]. Previous-
ly published studies have reported an increase in size and thick-
ness of the right ventricle in children and young adults with
moderate to severe CF [13,16], suggesting that these values
could represent the early stages of development and progres-
sion of long-term cardiac changes in patients with CF. In our
Table 5
Linear correlation coefficients between PFT, clinical scores, and echo findings.
Variable FEV1% ⁎ FVC% ⁎ SK ⁎ Brasﬁeld ⁎
RVAW (mm) −0.192 0.049 −0.295 −0.088
RVAW/BSA −0.217 −0.031 −0.311 −0.052
RVEDD (mm) 0.055 0.260 −0.066 −0.156
RVEDD/BSA 0.071 0.227 −0.271 −0.041
RVFA (%) −0.097 −0.016 −0.168 −0.055
TAPSE (mm) −0.029 0.178 0.150 −0.093
E-wave (cm/s) −0.028 −0.039 −0.007 0.028
A-wave (cm/s) 0.156 0.180 −0.231 −0.161
E/A ratio −0.054 −0.064 0.205 0.151
RPEP (ms) −0.311 −0.312 −0.192 −0.171
ACT (ms) 0.057 −0.080 0.125 0.108
RVET (ms) 0.235 0.196 0.375 0.299
Ratio RPEP/RVET −0.292 −0.234 −0.276 −0.284
Ratio ACT/RVET −0.104 −0.184 −0.019 −0.063
ST-wave (cm/s) 0.000 0.045 0.215 0.218
ET-wave (cm/s) −0.172 0.057 0.180 0.077
AT-wave (cm/s) 0.103 0.266 0.092 −0.080
ET/AT ratio −0.091 −0.151 0.124 0.205
FEV1 = forced expiratory volume in 1 s; FVC = forced vital capacity; (%) =
percent of predicted value; SK = Shwachman score.
See Table 3 legend for expansion of abbreviations.
⁎ pN0.05 for all values.
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thickness and size of the right ventricle between CF patients
and controls (pb0.001 and pb0.003 respectively), and also
between CF patients and published normal ranges for RV di-
mensions (22.3±4 vs. 14.6±1.6; pb0.001) [17], but in contrast
our patients had mild respiratory symptoms, with minor lung
deterioration and almost normal pulmonary function tests.
Raised pulmonary artery pressure is an independent
prognostic factor for a bad outcome. Prevalence of pulmonary
hypertension in CF patients with severe obstructive lung
disease is about 20% to 40%, and survival in this group is
reduced; whereas patients with better pulmonary function
have a much lower incidence of pulmonary hypertension and
a higher survival rate [3]. However, it has also been observed
that the presence of pulmonary hypertension is not always
followed by clinical evidence of cor pulmonale [3].
Doppler analysis of pulmonary blood flow has proven to be
a useful technique in the diagnosis of pulmonary artery hyper-
tension. Shortening of ACTb100 ms and values of RPEP/
RVET over normal or ACT/RVET below normal, are highly
suggestive of elevated PASP [15,18]. In our group of patients,
ACT, RVET and ACT/RVET ratio where shorter than in the
control group, while the RPEP/RVET ratio was increased, sug-
gesting slightly elevated PASP. Also, in the small subgroup in
which the pulmonary artery systolic pressure could be deter-
mined from tricuspid regurgitation, findings were consistent
with normal or slightly elevated PASP. Although evidence of
mild elevation of PASP was found in the group with FEV1%
values b85% predicted, no changes on geometry or function
of the right ventricle were observed, compared with the N85%
predicted group.
RVFA has been demonstrated to be a clinically feasible diag-
nostic tool for monitoring RV function in patients with lung dis-
ease [19]. Published studies of RV function by echocardiographyin CF patients with several degrees of lung disease are contradic-
tory. While there are authors showing that RV systolic function
seems to be preserved [3,20], others have found RV dysfunction
in up to 60% of the cases in the adult population with severe CF
using echocardiography [21], radionuclide angiography tech-
niques [22], and magnetic resonance imaging [19]. The degree
of dysfunction seems to parallel the severity of the disease,
especially when a concomitant pulmonary hypertension is pre-
sent [22]. Reported values for normal young adults are 0.40±
0.03 [6] and 0.41±0.15 [23] in two different papers. Our ado-
lescent control group had similar values 0.40±0.06, in contrast
with those of the CF group of 0.34±0.08, showing that RVFA
is mildly depressed in patients with CF. We suggest that a
mild degree of RV dysfunction is present in clinically stable
CF adolescent patients.
TAPSE is another geometry independent parameter that has
proven to be a rapid and non-invasive method of evaluating
right ventricular systolic function, with a close correlation
with RV ejection fraction as measured by radionuclide angiog-
raphy [6,24]. TAPSE has been found to be depressed in adult
CF patients with severe disease [21]. In our patients, TAPSE
values were decreased compared to controls, and also when
they were compared with published normal values (20.9±3.4
vs. 23.0±1.1; pb0.001) [25], suggesting that right ventricular
systolic dysfunction may occur at very early stages of the dis-
ease process.
Abnormalities of diastolic function are an early feature of
myocardial disease. Diastolic function of the RV in CF has
been shown to be abnormal in several studies [26] and correla-
tion between RV diastolic parameters and PASP has also been
reported in various chronic obstructive lung diseases [27]. In
our study we also found abnormalities in RV diastolic filling,
characterized by decreased peak velocity E, increased peak
velocity A, and low E/A ratio. All these values showed signif-
icant differences with our controls, and also with published
normal values [28].
TDE allows quantitative assessment of RV systolic and
diastolic function by means of measurement of myocardial veloc-
ities. The advantages of TDE variables are that they appear to be
more sensitive indicators of RV myocardial diastolic dysfunction
than Doppler RV variables, as they are less load dependent.
Early studies in adults have found that such abnormalities
comprised low ET, high AT, and low ET/AT values [29].
Our findings confirm this hypothesis. In adults, peak systolic
velocity (ST) b11.5 cm/s identifies the presence of RV systolic
dysfunction with a high sensitivity and specificity [30]. In our
group of patients the tricuspid peak systolic velocity was also
low and significantly different from healthy individual (12.6±2.0
vs. 14.0±2.9; pb0.05) and from published normal values in ado-
lescents (12.6±2.0 vs. 13.6±0.5; pb0.005) [31], suggesting RV
systolic dysfunction. Our results are similar to others, who found
RV dysfunction in patients with CF but with a more severe degree
of lung disease [23].
Previous studies have found that PFT correlate well with the
presence of pulmonary hypertension and RV abnormalities in
patients with severe CF [13]. In clinical practice, FEV1 and the
annual fall in FEV1 percentage predicted have been classically
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predict survival [32]. These parameters are reported to correlate
with genotype, sex, pancreatic and nutritional status, and col-
onization by P. aeruginosa [33]. In our group of patients their
pulmonary disease was best classified as mild, with FEV1%
and FVC% nearly normal (means 93.2 and 99.1 respectively).
In contrast with published papers [13,23], we did not find any
correlation between the RV echocardiographic parameters and
the FEV1 or FVC percent predicted values. We postulate that
as the diseases progresses thorough adolescence and adult life
and PFT deteriorates, correlation with RV abnormalities would
be closer.
Correlation between genotype and severity of pulmonary
disease is contradictory. Published data suggest that ΔF508
mutation has traditionally been related to more severe pulmo-
nary deterioration [34], while other mutations have been related
to milder forms of the disease [35]. In our study we were unable
to show differences between RV dysfunction and mutations in
the disease-causing gene in this age range.
In CF, impairment of mucociliary clearance and innate de-
fense mechanisms leads to susceptibility to chronic infections
by opportunistic bacteria. Most patients are initially colonized
by S. aureus and/or Haemophilus influenzae; however, by
adulthood P. aeruginosa emerges as the most prevalent CF
pathogen. Chronic colonization for P. aeruginosa is strongly
associated with respiratory deterioration and mortality [36],
for which patients colonized by P. aeruginosa would be
more prone to develop RV dysfunction, as lung diseases pro-
gress more rapidly in this group than in non-colonized patients.
In our group of patients we were unable to demonstrate a statis-
tically significant association between the presence of chronic
lung colonization and right ventricular abnormalities. We sug-
gest that this association may need some time to develop and
to prove any further correlation a longer time of exposition to
the pathogen, beyond adolescence would be required. Never-
theless, the limited number of patients for each subgroup did
not allow us to establish definitive conclusions on this particu-
lar issue.
Significant correlations between cor pulmonale and SK clin-
ical score have been found by some authors [13]. We were
unable to confirm this hypothesis. SK score was only mildly de-
pressed in our patients, and such correlation would probably
need a longer period of evolution and more clinical severity to
be present.
A limitation of this study is the relatively small sample
size. Although we have been able to show statistically signif-
icant differences between CF patients and healthy controls,
the sample size was insufficient to find differences in the sub-
group analysis.
Our findings show incipient alterations of cardiac function
in CF patients with mild disease. Since lung function in these
patients was almost normal, these findings cannot be explained
by the progression of pulmonary disease. Classically, the dete-
rioration of cardiac function in CF patients has been associated,
as in other progressive lung diseases, with the presence of hyp-
oxia. This explanation is not valid in this case as hypoxia is
unlikely to be present in these patients. Although hypoxia isnot a major mechanism for altered vascular structure at this
stage of the disease, chronic inflammation could also be respon-
sible for some degree of remodeling of pulmonary resistance
vessels and hence provoking mild elevations of PASP that sec-
ondarily could influence the right heart. Another possible mech-
anism is that, as occurs in other organs affected by CF, there is a
direct involvement of the disease on the heart. Recently, it has
been demonstrated that CFTR is involved in the regulation of
cardiomyocyte contraction, and it has also been postulated that
loss of CFTR function might leave CF patients at increased
risk of heart dysfunction and disease [37]. Any direct involve-
ment of the CF on the heart would be masked in advanced stages
of the disease, when changes secondary to pulmonary hyperten-
sion and hypoxia would predominate. Further investigation in
this field is necessary to determine the possibility that CF direct-
ly affect cardiac function.
In conclusion, our findings suggest that abnormalities in
the structure and function of the RV may be present during
adolescence at very early stages of the disease, when respirato-
ry manifestations are mild. These abnormalities are subclinical,
and do not correlate with the clinical scores, PFT, genotype,
chronic colonization, genotype, or pancreatic status. Whether
those changes are secondary to mild elevations of PASP, or
from direct involvement of cardiomyocytes in CF have to be
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